The Clinical Value Of Detecting Plasma VEGF Level In Patients With NSCLC

Objective: Lung cancer is one of the commonest neoplasms all over the world with the highest morbidity and mortality.The rapid development of modern medicine is not hesitate,however,improving the diagnosis and treatment of the early stage of lung cancer,seeking more effective tools or biomarkers for the estimation of response to therapy and prediction of disease progression,Having a better management for patients with lung cancer,all the above issues will be explored in this paper.Methods: We studied 49 newly diagnosed and primarily untreated advanced non-small cell lung cancer patients and 10 controls.Forty nine patients received platinum-based chemotherapy.Plasma VEGF levels were quantified in all samples at baseline and also before third and fifth chemotherapy cycle in 49 patients.And bounding up with response to therapy as assessed by chest computed tomography ahead the third and fifth chemotherapy cycle.Results: We observed that,(1)The plasma level of VEGF in patients with lung adenocarcinoma was higher than that in lung squamous cell carcinoma,P<0.05;(2)The level of plasma VEGF as biomarkers of lung adenocarcinoma and lung squamous cell carcinoma,the area under the curve(AUC)were 0.910 and 0.723,respectively(95%CI:0.813-1.000;0.537-0.909,respectively);their sensitivity was 76% and 87.5%respectively,and specificity was 90% and 50%,P <0.05;(3)The plasma level of VEGF was different in PR,SD and PD before the third chemotherapy and the fifth,P<0.05;(4)Prediction of disease progression by Plasma VEGF levels before the third cycle,which AUC was 0.857,with a sensitivity and specificity of 88.9% and 73.3%;And before the fifth cycle,which AUC was 0.856,with a and specificity of 77.8% and 83.3%;95%CI of the both were 0.746-0.963;0.729-0.983;P<0.05;(5)Plasma VEGF levels before the third and fifth cycle detected poor response to therapy,that AUC was 0.782 and0.854,with 95%CI 0.617-0.947 and 0.730-0.978,respectively;both sensitivity was high and more than 90%,both P<0.05.However plasma VEGF levels before the third and fifth cycle detected good response to treatment,which AUC were very low,0.218;0.146,respectively.Conclusion: The plasma VEGF levels as a specific biomarker of lung cancer has potential value.Monitoring of plasma VEGF levels during the course of first-line chemotherapy could identify patients who are likely to have insufficient response to therapy or disease progression at an early stage.This provides important information on whether we need to replace the treatment program,so it may help in individualizing treatment and could lead to better management of patients with the advanced stage of NSCLC.